The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (Ia), (Ib), (IIa) and (IIb), below: Formula (Ia), Formula (Ib), Formula (IIa), Formula (IIb).

##STR00001##

The present invention relates to a nanoparticle comprising a drug dimer and a use thereof. The nanoparticle comprising a drug dimer of the present invention can increase the drug content and improve the dispersibility of the drug. In addition, the nanoparticle has increased targeting efficiency. Therefore, an effective pharmacological effect can be obtained by using a drug in a less amount, and thus the nanoparticle has excellent commercial applicability.

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof: formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

##STR00001##

The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof: formula (I) and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of cancer. Further aspects of the present invention include combination therapies in which a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-cancer agent.

##STR00001##

Provided are a c-Myc protein inhibitor, and a preparation method therefor and use thereof. The c-Myc protein inhibitor selectively inhibits c-Myc protein. Therefore, the inhibitor can be used for prevention and treatment of diseases related to c-Myc protein disorders, such as cancers, cardiovascular and cerebrovascular diseases, diseases related to virus infection.

The present invention relates to a sterile, ready-to-use, aqueous composition of bortezomib that is stable over its shelf life.

The present invention relates to a sterile, ready-to-use, aqueous composition of bortezomib that is stable over its shelf life.

The present invention provides the use of vitamin K2 compositions for the treatment of drug-induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug-induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.

The present invention provides the use of vitamin K2 compositions for the treatment of drug-induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug-induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.

The present invention provides the use of vitamin K2 compositions for the treatment of drug-induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug-induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.